

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Drug Evaluation and Research (CDER)  
ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE**

**DRAFT AGENDA  
November 19, 2008 (Afternoon session)**

*The committee will discuss NDA 022-153, oritavancin, Targanta Therapeutics Corp., proposed for the treatment of complicated skin and skin structure infection.*

1 pm	Call to Order and Opening Remarks	Acting Chair, Anti-Infective Drugs Advisory Committee
	Introduction of Committee Conflict of Interest Statement	<b>Janie Kim, PharmD</b> Designated Federal Officer
1:15 pm	Introduction/Background Applicants presentation	TBD Targanta Therapeutics Corp
2:00 pm	FDA Presentation	TBD
2:45 pm	Questions/clarifications	
4:00 pm	Break	
4:15 pm	Open Public Hearing	
4:30 pm	Charge and questions to the committee	
5:30 pm	Adjourn	